Lazar Dimitrov

Lazar Dimitrov began their career in 1998 as an Analyst in the Mergers and Acquisitions Group at Merrill Lynch. In 2000, they moved to Rho Ventures as a Venture Analyst. In 2009, they became a Postdoctoral Fellow at the Fred Hutchinson Cancer Research Center, where they investigated the transcription profile of aged cells in their Ph.D. advisor's lab. In 2010, they continued their postdoctoral work at the Howard Hughes Medical Institute. In 2014, they joined Crystal Bioscience as an Associate Scientist, which was later acquired by Ligand Pharmaceuticals. In 2015, they moved to Clarus Ventures as a Principal. In 2018, they joined The Blackstone Group as a Principal. In 2020, they joined Day One Biopharmaceuticals as Vice President of Business Development, where they negotiated the exclusive global license agreement with Merck KGaA, the global collaboration agreement with Foundation Medicine, a pre-clinical collaboration, two contingency-fee patient recruitment agreements, and an exclusive academic license. In 2022, they moved to Bright Peak Therapeutics as Senior Vice President of Corporate Development.

Lazar Dimitrov began their educational career at Mathematics High School in Plovdiv, Bulgaria from 1987 to 1992. Lazar then attended Lester B. Pearson College from 1992 to 1994, where they earned an International Baccalaureate. Lazar went on to Dartmouth College from 1994 to 1998, where they earned an A.B. in Economics and Mathematics. Finally, they attended the University of Washington from 2002 to 2009, where they earned a Ph.D. in Genome Sciences.